Priscilla B. Caguioa

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Anthony T.�C. Chan, V.H.F. Lee, R-L. Hong et al. · Annals of Oncology · 2022 · 100 citations · Full text

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Jae-Yong Kwak, Sung‐Hyun Kim, Suk Joong Oh et al. · Clinical Cancer Research · 2017 · 74 citations

Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma.

Paul J. Hesketh, Priscilla B. Caguioa, Howard K. Koh et al. · Journal of Clinical Oncology · 1993 · 59 citations